The $518 million acquisition, announced in July, is expected to close Oct. 29. The stockholders’ votes approved the issuance of shares of Biovenus Class A common stock to the stockholders of Misonix.
“The combination with Misonix creates significant value and provides a deeper global portfolio of pain treatments, restorative therapies and surgical solutions for patients,” Bioventus CEO Ken Reali said in an Oct. 26 news release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
